Mary Ann Liebert Inc.: Multiple Dosing of Long-Acting Rilpivirine in a Model of HIV Pre-Exposure Prophylaxis
July 25, 2019
July 25, 2019
NEW ROCHELLE, New York, July 25 -- Mary Ann Liebert Inc. issued the following news release:
A long-acting antiretroviral agent such as rilpivirine could further improve pre-exposure prophylaxis (PrEP), already shown to be safe and effective at preventing AIDS in high risk populations, as it could overcome problems with poor medication adherence. A new study examining the safety, acceptability, and effectiveness of multiple doses of injected rilpivirine is published in AIDS Research . . .
A long-acting antiretroviral agent such as rilpivirine could further improve pre-exposure prophylaxis (PrEP), already shown to be safe and effective at preventing AIDS in high risk populations, as it could overcome problems with poor medication adherence. A new study examining the safety, acceptability, and effectiveness of multiple doses of injected rilpivirine is published in AIDS Research . . .